BioGeometry and Sanyou Bio Collaborate to Develop AIGC Driven Antibody Drug Discovery Platform
Shots:
- BioGeometry and Sanyou Bio have entered into a strategic partnership agreement for the development of AIGC-based antibody drug discovery platform
- The collaboration will utilize BioGeometry's generative AI antibody design platform (GeoBiologics) and Sanyou Bio's wet lab expertise to establish a Dry-Wet antibody R&D platform
- The platform will be leveraged for the advancement of large molecule drug pipeline and incubating innovative projects for market expansion opportunities
Ref: Numab | Image: Numab
Related News:- Numab Therapeutics and Ono Pharmaceutical Join Forces for the Development of NM49 for Treating Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
